Study Tracker
Every study we cite across the library, newest first. This is our moat: a living, auto-dated research feed. Automated PubMed ingestion arrives in a later session — the structure below is built to absorb it without changes.
- 2023Assessment of anterior pituitary reserve capacity based on growth hormone response to growth hormone-releasing peptide-2 test in the elderly
Teramoto S, Tahara S, Hattori Y, Kondo A, Morita A · Growth Hormone & IGF Research · PMID 37295337 · model: human
Prospective use of the GHRP-2 stimulation test in elderly patients demonstrating robust and measurable GH responses, supporting GHRP-2's utility as a human pituitary reserve assessment tool.
- 2023Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
Frias JP, Deenadayalan S, Erichsen L, Knop FK, Lingvay I, Macura S, Mathieu C, Pedersen SD, Davies M · Lancet · PMID 37364590 · model: human
Phase 2 RCT in type 2 diabetes showing the CagriSema combination (cagrilintide plus semaglutide, each 2.4 mg) produced greater weight and glycemic reductions than either agent alone.
- 2023Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, Thomas MK, Hartman ML, Haupt A, Milicevic Z, Coskun T · Lancet · PMID 37385280 · model: human
Phase 2 RCT in type 2 diabetes showing retatrutide markedly lowered HbA1c and body weight versus placebo and an active comparator over the trial period.
- 2023Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornøe CW, Ryan DH · The New England Journal of Medicine · PMID 37952131 · model: human
SELECT outcome trial showing semaglutide reduced major adverse cardiovascular events versus placebo in people with obesity and established cardiovascular disease but without diabetes.
- 2023Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML · The New England Journal of Medicine · PMID 37366315 · model: human
Phase 2 RCT in adults with obesity where retatrutide produced dose-dependent weight loss reaching roughly 24% at the 12 mg dose over 48 weeks versus placebo.
- 2022Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A · The New England Journal of Medicine · PMID 35658024 · model: human
SURMOUNT-1 phase 3 RCT in adults with obesity without diabetes, showing a mean ~20.9% body-weight reduction at the 15 mg dose over 72 weeks versus placebo.
- 2021Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
Lau DCW, Erichsen L, Francisco AM, Satylganova A, le Roux CW, McGowan BM, Pedersen SD, Pietiläinen KH, Rubino DM, Batterham RL · Lancet · PMID 34798060 · model: human
Phase 2 dose-finding RCT in overweight or obesity where cagrilintide produced up to ~10.8% mean weight loss at 2.4 mg over 26 weeks, with a liraglutide 3.0 mg active comparator.
- 2021Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF · The New England Journal of Medicine · PMID 33567185 · model: human
STEP 1 phase 3 RCT in adults with overweight or obesity without diabetes, showing a mean ~14.9% body-weight reduction on semaglutide 2.4 mg weekly over 68 weeks versus placebo.
- 2021Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, Rosenstock J, Shimomura I, Viljoen A, Wadden TA, Lingvay I · Lancet · PMID 33667417 · model: human
STEP 2 phase 3 RCT showing semaglutide 2.4 mg produced significant weight loss in adults who had both overweight/obesity and type 2 diabetes.
- 2021Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, Liu B, Cui X, Brown K · The New England Journal of Medicine · PMID 34170647 · model: human
SURPASS-2 head-to-head phase 3 RCT showing tirzepatide produced greater reductions in HbA1c and body weight than semaglutide 1 mg in adults with type 2 diabetes.
- 2019Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing
Gwyer D, Wragg NM, Wilson SL · Cell and Tissue Research · PMID 30915550 · model: animal
Revue de la littérature préclinique concluant que le BPC-157 accélère la réparation des tendons, ligaments et muscles dans divers modèles de lésion.
- 2019Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing
Gwyer D, Wragg NM, Wilson SL · Cell and Tissue Research (référence composé-parent BPC-157) · PMID 30915550 · model: animal
Référence sur le composé parent (BPC-157) — la PDA elle-même n'a pas d'études publiées indépendantes ; incluse uniquement comme contexte sur la molécule apparentée.
- 2018Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Vascular Recruitment and Gastrointestinal Tract Healing
Sikiric P, et al. · Current Pharmaceutical Design · PMID 29879879 · model: animal
Revue situant les effets gastro-protecteurs et vasculaires du BPC-157 dans les modèles précliniques autour de l'angiogenèse.
- 2018Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data
Pickart L, Margolina A · International Journal of Molecular Sciences · PMID 29986520 · model: in-vitro
Revue documentant la modulation par le GHK-Cu de milliers de gènes humains liés à la réparation tissulaire et à la défense antioxydante.
- 2018The Safety and Efficacy of Growth Hormone Secretagogues
Sigalos JT, Pastuszak AW · Sexual Medicine Reviews · PMID 28400207 · model: human
Clinical review of GH secretagogues (including GHRP-2) covering mechanism, human efficacy data, and safety considerations including the cortisol and prolactin co-secretion characteristic of GHRP-2.
- 2016Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB · The New England Journal of Medicine · PMID 27295427 · model: human
LEADER outcome trial showing liraglutide reduced major adverse cardiovascular events versus placebo in adults with type 2 diabetes at high cardiovascular risk.
- 2015A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DCW, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JPH · The New England Journal of Medicine · PMID 26132939 · model: human
SCALE Obesity and Prediabetes RCT showing liraglutide 3.0 mg daily produced a mean ~8% body-weight reduction over 56 weeks versus placebo in adults without diabetes.
- 2015GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration
Pickart L, Vasquez-Soltero JM, Margolina A · BioMed Research International · PMID 26236730 · model: in-vitro
Revue des effets du GHK sur le collagène, les fibroblastes et les voies de réparation cutanée à concentrations nanomolaires.
- 2012Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin
Stanley TL, Falutz J, Mamputu JC, Soulban G, Potvin D, Grinspoon SK · Clinical Infectious Diseases · PMID 22495074 · model: human
Secondary analysis of phase 3 data linking tesamorelin-induced visceral fat reduction to improvements in triglycerides and other cardiometabolic markers.
- 2012Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications
Goldstein AL, Hannappel E, Sosne G, Kleinman HK · Expert Opinion on Biological Therapy · PMID 22074294 · model: animal
Revue des rôles de la thymosine β4 dans la liaison à l'actine, la migration cellulaire et la réparation tissulaire, et de ses premières applications cliniques.
- 2011MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study
Adunsky A, Chandler J, Heyden N, Lutkiewicz J, Scott BB, Berd Y, Liu N, Papanicolaou DA · Archives of Gerontology and Geriatrics · PMID 21067829 · model: human
Phase IIb RCT in hip fracture patients aged 65+: trial was terminated early due to a congestive heart failure safety signal; MK-0677 was concluded to have an unfavorable safety profile in this frail elderly population.
- 2011The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration
Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS · Journal of Applied Physiology · PMID 21030672 · model: in-vitro
Étude cellulaire reliant le BPC-157 à la croissance, la survie et la migration des ténocytes via la voie FAK-paxilline.
- 2010Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data
Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, Marsolais C, Turner R, Grinspoon S · The Journal of Clinical Endocrinology and Metabolism · PMID 20554713 · model: human
Pooled analysis of two phase 3 RCTs showing tesamorelin significantly reduced visceral adipose tissue vs. placebo over 26 weeks in HIV-infected adults with lipodystrophy.
- 2009Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus
Venkova K, Fraser G, Hoveyda HR, Greenwood-Van Meerveld B · The Journal of Pharmacology and Experimental Therapeutics · PMID 19289567 · model: animal
Ipamorelin accelerated gastric emptying and restored GI motility in a rat model of postoperative ileus, pointing to potential GI applications beyond GH stimulation — though not yet tested in humans.
- 2008Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial
Nass R, Pezzoli SS, Oliveri MC, Patrie JT, Harrell FE Jr, Clasey JL, Heymsfield SB, Bach MA, Vance ML, Thorner MO · Annals of Internal Medicine · PMID 18981485 · model: human
Twelve-month RCT in 65 healthy older adults: MK-677 raised GH and IGF-1 and increased fat-free mass (+1.6 kg vs. placebo), but worsened insulin sensitivity, raised fasting glucose, and caused edema — with no improvement in strength or function.
- 2008Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial
Sevigny JJ, Ryan JM, van Dyck CH, Peng Y, Lines CR, Nessly ML, MK-677 Protocol 30 Study Group · Neurology · PMID 19015485 · model: human
RCT in 563 Alzheimer disease patients: MK-677 25 mg/day raised IGF-1 by 72.9% (confirming target engagement), but was ineffective at slowing the rate of disease progression — no significant differences on any cognitive or functional measure.
- 2008Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation
Falutz J, Allas S, Mamputu JC, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S · AIDS · PMID 18690162 · model: human
Safety extension data over 52 weeks showing sustained visceral fat reduction and a tolerability profile consistent with the phase 3 trial period.
- 2008Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease
Kannengiesser K, Maaser C, Heidemann J, et al. · Inflammatory Bowel Diseases · PMID 18092346 · model: animal
Étude sur modèles murins de MICI rapportant une réduction des lésions coliques et des cytokines inflammatoires sous KPV.
- 2008PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation
Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, Yan Y, Sitaraman S, Merlin D · Gastroenterology · PMID 18061177 · model: animal
Étude sur cellules et modèles murins de colite montrant que le KPV entre dans les cellules via PepT1 et atténue l'inflammation médiée par NF-κB.
- 2006Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA · The Journal of Clinical Endocrinology and Metabolism · PMID 16352683 · model: human
Pharmacokinetic/pharmacodynamic study in healthy adults showing that a single CJC-1295 injection produced dose-dependent, sustained increases in GH and IGF-1 for up to nine days — the only published human data on this compound.
- 2006Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?
Walker RF · Clinical Interventions in Aging · PMID 18046908 · model: human
A clinical review arguing that sermorelin, by stimulating physiological pulsatile GH release, offers advantages over direct GH replacement in adult-onset GH insufficiency — though the argument is mechanistic rather than RCT-supported.
- 2005Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog
Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP · Endocrinology · PMID 15817669 · model: animal
Identification and characterization of CJC-1295 in rats, demonstrating that albumin conjugation of GHRH(1-29) produces a long-acting GRF receptor agonist with sustained GH-stimulating activity.
- 2005Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues
Goldstein AL, Hannappel E, Kleinman HK · Trends in Molecular Medicine · PMID 16099219 · model: in-vitro
Revue expliquant comment ce peptide séquestreur d'actine devient un signal de réparation extracellulaire lorsqu'il est libéré après une lésion.
- 2002Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury
Sosne G, Szliter EA, Barrett R, Kernacki KA, Kleinman H, Hazlett LD · Experimental Eye Research · PMID 11950239 · model: animal
Étude in vivo chez la souris montrant que la thymosine β4 topique accélère la ré-épithélialisation cornéenne et réduit l'inflammation après lésion.
- 1998Ipamorelin, the first selective growth hormone secretagogue
Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH · European Journal of Endocrinology · PMID 9849822 · model: animal
Original characterization of ipamorelin in pig and rat models, establishing its potent and selective stimulation of GH release without significant ACTH or cortisol elevation — the key selectivity finding that distinguishes it from older GHRPs.